Q-omics provides the consensus-scored USP30 profile across patient tissues and cancer cell-line models. USP30 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USP30 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, USP30 protein abundance shows 28,078 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where USP30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP30 survival associations across molecular data types. USP30 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP30 RNA expression–survival associations across cancer types. High USP30 expression shows unfavorable associations in LUSC, CHOL and UVM, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP30 RNA expression.
This table summarizes USP30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for USP30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP30 shows lower tumor expression in COAD, THCA, LUAD and BRCA and higher tumor expression in LIHC and BLCA. The COAD box plot shows higher USP30 RNA expression in normal versus tumor tissue (log2 FC = −0.738, t-test p < 0.001).
This table shows molecular features associated with USP30 in patient tissues and cancer cell lines. In patient samples, USP30 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, USP30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
